The Amyloidosis Channel is supported with funding from Prothena (Silver).
The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMW 2019 | Lenalidomide and Ixazomib: a successful amyloidosis treatment combination?
Oliver Charles Cohen
• 14 Sep 2019
Dr Oliver Charles Cohen, MD, of the University College London Hospitals NHS Foundation Trust, London, UK, discusses the challenges of amyloidosis, and the newfound promise of lenalidomide combined with ixazomib in its treatment. This interview was recorded at the International Myeloma Workshop (IMW) 2019, in Boston, MA.
